Clinical trials: Platelet Transfusion Refractoriness
Platelet Transfusion Refractoriness, Acute Leukemia in Remission
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL
Alloimmune-mediated platelet transfusion refractoriness(PTR) was usually caused by repeated blood transfusions and pregnancy and accounts for about 20-25% of PTR patients.
- Trial name
- NCT04846439
- Testing
- CAR-T infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Platelet Refractoriness in Adult Acute Leukemia
Incidence of Platelet Refractoriness in Adult Acute Leukemia Patients Receiving Prestorage Filtered Blood and Comparing With Historical Control
This research project is evaluate the incidence of platelet refractoriness in newly diagnosed acute leukemia patients receiving PFB during induction and first consolidation phase chemotherapy compared to 2 historical control…
- Trial name
- PTR (NCT06325553)
- Where
- Thailand
- Volunteers
- 252 people
- Sponsor
- Siriraj Hospital
Thrombocytopenia, Alloimmune Platelet Refractoriness
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Background: Platelets are tiny cells in the blood that help stop bleeding. Thrombocytopenia happens when people do not have enough normal platelets.
- Trial name
- NCT02298933
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Platelet Transfusion Refractoriness
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.
- Trial name
- NCT06792019
- Testing
- CM313(SC) injection-low dose, CM313(SC) injection-high dose
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Keymed Biosciences Co.Ltd
Thrombocytopenia, Platelet Transfusion Refractoriness
Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion
Background: Platelets are blood cells that help blood clot. Some people have what is called thrombocytopenia. This means they have a low blood platelet count. They need platelet transfusions very often.
- Trial name
- NCT02858323
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Thrombocytopenia, Hematologic Malignancy
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate…
- Conditions
- Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders
- Trial name
- NCT04631211
- Testing
- Thrombosomes, Liquid Stored Platelets (LSP)
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 21 people
- Sponsor
- Cellphire Therapeutics, Inc.
Hematological Patients, Bleeding
Administration of Fibrinogen Concentrate for Refractory Bleeding
Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients with thrombocytopenia. Patients with bone marrow failure secondary to haematological malignancy and chemotherapy frequently receive…
- Conditions
- Hematological Patients, Bleeding, Platelet Refractoriness
- Trial name
- FORMAT (NCT05091684)
- Testing
- Fibrinogen Concentrate Human
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Platelet Transfusion Refractoriness
Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR
The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR…
- Trial name
- NCT05761457
- Testing
- Cryopreserved autologous platelet transfusion
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Platelet Refractoriness
Platelet Agregation in Patients on ECMO
An observational study in which investigators will observe platelet inhibition in patients on VA ECMO acorrding to treatment with P2Y12 inhibitor.
- Trial name
- NCT05542134
- Testing
- P2Y12 Platelet Aggregation Inhibitor
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- University Medical Centre Ljubljana
Platelet Transfusion Refractoriness
Platelet Transfusion Refractoriness
Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia.
- Trial name
- ACERTP (NCT05399693)
- Testing
- platelet transfusion
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Cerebrovascular Disorders, Platelet Refractoriness
Platelet Antisedimentation Rate and Multiplate Exams in Patients on Antiplatelet Therapy and Controls
To search for simple laboratory methods selecting patients with low/non-responsiveness to P2Y12 receptor antagonists.
- Conditions
- Cerebrovascular Disorders, Platelet Refractoriness, Platelet Aggregation, Spontaneous
- Trial name
- NCT03679858
- Testing
- Platelet function test
- Where
- Hungary
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pecs
Platelet Transfusion Refractoriness (PTR), Thrombocytopenia
The SOLID Platelet Study
Background: Platelets are cell fragments in the blood that help it clot. Some people get very low platelet counts during a disease or treatment. Low platelet counts can cause severe bleeding.
- Trial name
- NCT03712618
- Testing
- Platelet Transfusion - LONG Platelet Transfusion, Platelet Transfusion - SHORT Platelet Transfusion
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet…
- Trial name
- NCT07072247
- Testing
- CD19 and BCMA-targeted allogeneic CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Platelet Refractoriness, Hematologic Malignancy
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
Some of the treatments for cancer can cause platelets (the part of the blood that helps with clotting) to decrease. If they are too low, then clinicians may recommend a transfusion (getting platelets from another person added to…
- Trial name
- NCT05284032
- Testing
- isatuximab 10 mg/kg
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Firas El Chaer, MD
Severe Aplastic Anemia, Platelet Transfusion Refractoriness
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR).
- Trial name
- NCT06254560
- Testing
- Rituximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematological Malignancies, Platelet Transfusion Refractoriness (PTR)
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of…
- Conditions
- Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
- Trial name
- AB-HLA-2026 (NCT07635511)
- Testing
- Acalabrutinib maleate, bortezomib, HLA-matched or crossmatched irradiated platelets
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Aplastic Anemia, Platelet Transfusion Refractoriness
Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
This is a phase 1, prospective, single-arm, open-label study. The aim of this study is to evaluate the transfusion responses of platelet increment by using Daratumumab among aplastic anemia patients with platelet transfusion…
- Trial name
- NCT05832216
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Blood Disease, Platelet Refractoriness
HPA Antibodies and the Distribution of Antigen and Antibodies
By detecting platelet antibodies of participants and then further to identify their genotype and analyzing laboratory examination, the investigators will obtain positive frequency of HPA antibodies, the distribution of HPA…
- Conditions
- Blood Disease, Platelet Refractoriness, Antibody-mediated Rejection
- Trial name
- NCT03408158
- Testing
- same type infusion of main HPA antigen
- Where
- China
- Volunteers
- 6,170 people
- Sponsor
- Guangzhou First People's Hospital